Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study

Autor: Taylor, P, Krogulec, M, Dudek, A, Dudler, J, Drescher, E, Cseuz, R, Kausiene, R, Andersone, D, Unikiene, D, Sanchez Burson, J, Blanco Alonso, R, Dvorak, Z, Ghizdavescu, A, Irto, I, Larsson, E, Bello, N, Barry, J, Durand, F, Holzkaemper, T, Otawa, S, De Bono, S, Keystone, E, Rubbert-Roth, A, Combe, B, De La Torre, I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::e4fd0bf810e9400e6dc1f5229676e6d9
https://doi.org/10.1093/rheumatology/kex061.001

Baricitinib inhibits radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis (RA) and an inadequate response to csDMARDs

Autor: van der Heijde, D, Dougados, M, Chen, YC, Greenwald, M, Drescher, E, Klar, R, Xie, L, de la Torre, I, Rooney, T, Witt, S, Schlichting, D, de Bono, S, Emery, P, Röhl, K

Publikováno v: 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20170906-20170909; Stuttgart; DOCRA.24 /20170904/

Background: Baricitinib (bari), a JAK1/2 inhibitor, was efficacious in a 24-week (wk) Ph 3 study in patients (pts) with active RA and an inadequate response (IR) to conventional synthetic DMARDs (csDMARDs) (RA-BUILD). The objective of this analysis w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cdce041c947e07a80e303a15fed1dd9

BARICITINIB INHIBITS RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE AT 1 YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS)

Autor: Genovese, M., Heijde, D. van der, Dougados, M., Chen, Y., Greenwald, M., Drescher, E., Klar, R., Xie, L., Torre, I. de la, Rooney, T., Witt, S., Schlichting, D., Bono, S. de, Emery, P.

Publikováno v: Internal Medicine Journal, 47, 32-32

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8914135fca47d83f6cf88b14e67480cc
https://hdl.handle.net/1887/114605

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

Autor: Genovese, MC, Keystone, E, Taylor, P, Drescher, E, Berclaz, P-Y, Lee, CH, Schlichting, DE, Beattie, SD, Fidelus-Gort, RK, Luchi, ME, Macias, W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::725b4548038b6ec39705f1527c04d94c
https://ora.ox.ac.uk/objects/uuid:43610c22-550d-430a-b111-678baf5561ff